首页> 外文期刊>RSC Advances >Cav2.2 and Cav3.1 calcium channel inhibitors from Valeriana jatamansi Jones
【24h】

Cav2.2 and Cav3.1 calcium channel inhibitors from Valeriana jatamansi Jones

机译: Valeriana jatamansi Jones的Ca v 2.2和Ca v 3.1钙通道抑制剂

获取原文
           

摘要

In China, the roots and rhizomes of Valeriana jatamansi Jones are traditionally used to treat gastrointestinal and rheumatic pain. Small molecule inhibitors of N-type (Cav2.2) and T-type (Cav3.1–3.3) calcium channels have become attractive resources in analgesic drug development. Therefore, in the present study, the isolated compounds (1–13) from V. jatamansi, including three new valepotriates (1–3), were initially evaluated on Cav2.2 and Cav3.1. As a result, compounds 1–12 showed weak to potent inhibition on Cav2.2 peak currents at 30 μM. Among them, compounds 1, 6, 7, 11 and 12 exhibited significant antagonistic effects, with EC50 values of 4.33, 2.18, 1.13, 2.70 and 7.8 μM, respectively. Meanwhile, the aforementioned compounds exhibited 18.2 ± 2.5% to 49.2 ± 7.1% peak current inhibition on Cav3.1 at 30 μM. In addition, they also exhibited noticeable specificity against Cav1.2, Cav2.1, and KCNH2 (hERG) channels.
机译:在中国, Valeriana jatamansi Jones的根和根茎传统上用于治疗胃肠道和风湿性疼痛。 N型(Ca v 2.2)和T型(Ca v 3.1-3.3的小分子抑制剂钙通道已成为止痛药开发中的诱人资源。因此,在本研究中,从 V中分离出化合物(1-13)。最初对jatamansi (包括3个新的戊三酸酯)(1-3)进行了Ca v 2.2和Ca v 评估 3.1。结果,化合物1-12在30μM时对Ca v 2.2峰值电流表现出弱至强的抑制作用。其中,化合物1、6、7、11和12表现出明显的拮抗作用,EC 50 值分别为4.33、2.18、1.13、2.70和7.8μM。同时,上述化合物在30μM时对Ca v 3.1的峰值电流抑制率为18.2±2.5%至49.2±7.1%。此外,它们还对Ca v 1.2,Ca v 2.1和KCNH2(hERG)表现出明显的特异性。渠道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号